Vimizim(elosulfase alfa)
Vimizim (elosulfase alfa) is an enzyme pharmaceutical. Elosulfase alfa was first approved as Vimizim on 2014-02-14. It is used to treat mucopolysaccharidosis IV in the USA. It has been approved in Europe to treat mucopolysaccharidosis IV.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Vimizim
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Elosulfase alfa
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Vimizim | elosulfase alfa | BioMarin Pharmaceutical | N-125460 RX | 2014-02-14 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vimizim | Biologic Licensing Application | 2021-01-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mucopolysaccharidosis iv | — | D009085 | E76.210 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
elosulfase alfa, Vimizim, BioMarin Pharmaceutical Inc. | |||
| 2121-02-14 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1322 | Injection, elosulfase alfa, 1 mg |
Clinical
Clinical Trials
264 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mucopolysaccharidosis iv | D009085 | — | E76.210 | 2 | 5 | 3 | — | 4 | 12 |
| Mucopolysaccharidoses | D009083 | — | E76.3 | 2 | 5 | 3 | — | 4 | 12 |
| Syndrome | D013577 | — | — | 1 | 4 | 2 | — | 1 | 7 |
| Osteochondrodysplasias | D010009 | Orphanet_800 | G71.13 | — | — | 1 | — | 3 | 4 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Elosulfase alfa |
| INN | elosulfase alfa |
| Description | Elosulfase alfa, sold under the brand name Vimizim, is a medication used for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108676 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | ODJ69JZG85 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vimizim – BioMarin Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,027 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vimizim
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,745 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use